Incyte Corporation $INCY Stock: State of Wyoming Reduces Stake

Posted by Geri Gentry on Oct 31st, 2026

State of Wyoming trimmed its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 33.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 23,586 shares of the biopharmaceutical company’s stock after selling 11,939 shares during the quarter. Incyte accounts for approximately 0.2% of State of Wyoming’s holdings, making the stock its 20th biggest holding. State of Wyoming’s holdings in Incyte were worth $2,862,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of INCY. BlackRock Inc. purchased a new stake in Incyte during the second quarter worth $2,044,189,000. Wellington Management Group LLP increased its holdings in shares of Incyte by 9.5% in the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after acquiring an additional 309,385 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Incyte by 10.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after acquiring an additional 187,354 shares during the period. Legal & General Group Plc bought a new position in shares of Incyte in the 2nd quarter worth $182,054,000. Finally, Pacer Advisors Inc. raised its position in shares of Incyte by 2.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock worth $163,869,000 after acquiring an additional 37,790 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $104.00 price objective on shares of Incyte in a research report on Thursday, August 13th. Benchmark reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, October 13th. Wells Fargo & Company reduced their target price on shares of Incyte from $128.00 to $127.00 and set an “equal weight” rating for the company in a report on Friday. Morgan Stanley started coverage on shares of Incyte in a research report on Tuesday, October 20th. They set an “equal weight” rating and a $119.00 price target for the company. Finally, Oppenheimer set a $152.00 price target on shares of Incyte in a report on Tuesday. Twelve analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $132.90.

Check Out Our Latest Analysis on INCY

Incyte Trading Up 3.1%

Shares of INCY stock opened at $120.39 on Friday. Incyte Corporation has a 12-month low of $89.25 and a 12-month high of $132.60. The business’s fifty day simple moving average is $120.49 and its 200-day simple moving average is $108.14. The company has a market cap of $24.40 billion, a PE ratio of 64.04, a PEG ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter last year, the firm earned $2.26 EPS. The business’s quarterly revenue was up 14.0% on a year-over-year basis. On average, equities analysts forecast that Incyte Corporation will post 1.97 earnings per share for the current year.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Insider Buying and Selling

In other Incyte news, insider Pablo Cagnoni sold 2,642 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider directly owned 183,200 shares in the company, valued at approximately $20,648,472. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Incyte Company Profile

(Free Report)

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.